100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
RAPS Practice Exam 2024 (Devices) Questions and Answers $13.49   Add to cart

Exam (elaborations)

RAPS Practice Exam 2024 (Devices) Questions and Answers

 2 views  0 purchase
  • Course
  • RAPS
  • Institution
  • RAPS

RAPS Practice Exam 2024 (Devices) Questions and Answers

Preview 3 out of 19  pages

  • October 30, 2024
  • 19
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • RAPS
  • RAPS
avatar-seller
millyphilip
RAPS Practice Exam 2024 (Devices)
Questions and Answers

Prior iito iiinitiating iia iiclinical iitrail, iithe iicompany iidiscovers iithat iithe iinon-clinical iistudy
iiresults iiwere iiincorrectly iidocumented. iiWhich iiof iithe iifollowing iiis iithe iiMOST
iiappropriate iicourse iiof iiaction iifor iithe iicompany?


a) iiNotify iithe iiIRB iiethics iicommittee iiand iiobtain iia iire-approval iifor iithe iitrial
b) iiProceed iiwith iithe iiclinical iitrial, iibut iiinitiate iiprotocol iiamendments iito iiaddress iithe
iierrors
c) iiRe-evaluate iithe iinonclinical iidata iibefore iiproceeding iiwith iithe iiclinical iitrial
d) iiRevalidate iithe iiprotocol iiand iirepeat iithe iinonclinical iistudies iiif iinecessary ii-
iiAnswers ii-c) iiRe-evaluate iithe iinonclinical iidata iibefore iiproceeding iiwith iithe iiclinical
iitrial


Explanation: ii
Ensuring iithe iiaccuracy iiof iinonclinical iidata iiis iicrucial iibefore iistarting iia iiclinical iitrial.
iiRe-evaluating iithe iidata iiwill iihelp iiconfirm iithat iithe iifoundation iifor iithe iiclinical iistudy
iiis iireliable iiand iimeets iiregulatory iirequirements.


Your iicompany iiis iiplanning iito iimarket iia iiClass iiII iistand-alone iimedical iidevice
iisoftware iiin iithe iiUS. iiThe iisoftware iiwill iinot iibe iidistributed iiin iipackaged iiform iiand iiwill
iiinstead iibe iiprovided iifor iidownload iifrom iithe iicompany iiwebsite. iiAs iia iiregulatory
iilead, iiyou iiare iiasked iito iiprovide iiguidance iion iiUnique iiDevice iiIdentifier ii(UDI)
iicompliance iifor iithis iiadvice. iiYou iiadvise iithe iidevelopment iiteam iithat iithe iiProduct
iiIdentifier ii(PI) iiwill iineed iito iiinclude iithe iisoftware iiversion iinumber. iiWhen iiasked iihow
iithe iiUDI iimust iibe iipresented, iihow iido iiyou iiadvise iithe iiteam?


a) iiThe iiUDI iishould iibe iiconveyed iiin iian iieasily iireadable iiformat iiwithin iithe iisoftware
iiinterface iior iion iithe iiwebsite.
b) iiThe iiUDI iishould iibe iiconveyed iiin iian iieasily iireadable iiformat iithat iican iibe
iiaccessed iithrough iithe iiwebsite.
c) iiThe iiUDI iishould iibe iiconveyed iiin iian iieasily iireadable iiformat iiwithin iithe iisoftware
iiitself.
d) iiA iiand iiC ii- iiAnswers ii-d) iiA iiand iiC

Explanation: ii
a) iiThe iiUDI iishould iibe iiconveyed iiin iian iieasily iireadable iiformat iiwithin iithe iisoftware
iiinterface iior iion iithe iiwebsite. iiThis iiensures iithe iiUDI iiis iiavailable iiin iithe iicontext
iiwhere iithe iisoftware iiis iiaccessed iior iiused.

,c) iiThe iiUDI iishould iibe iiconveyed iiin iian iieasily iireadable iiformat iiwithin iithe iisoftware
iiitself. iiThis iiensures iithat iiusers iican iifind iiand iiverify iithe iiUDI iionce iithe iisoftware iiis
iidownloaded iiand iiin iiuse.
Both iia iiand iic iiensure iithat iithe iiUDI iiis iipresented iiin iia iiformat iithat iiis iiaccessible iiand
iireadable iiboth iiat iithe iipoint iiof iidownload iiand iiwithin iithe iisoftware.


What iisource iishould iithe iiregulatory iiprofessional iiconsult iito iidetermine iiwhen iia
iiproduct's iipatent iiand iiexclusivity iiwill iiexpire?


a) iiFederal iiRegister
b) iiThe iiOrange iiBook
c) iiPatent iiand iiTrademark iiOffice
d) iiCopyright iiOffice ii- iiAnswers ii-b) iiThe iiOrange iiBook

Explanation:
The iiOrange iiBook ii(Approved iiDrug iiProducts iiwith iiTherapeutic iiEquivalence
iiEvaluations) iilists iipatents iiand iiexclusivity iiinformation iifor iiFDA-approved iidrug
iiproducts. iiIt iiprovides iidetails iion iipatent iiexpiration iidates iiand iiperiods iiof iiexclusivity.


You iiare iitasked iiwith iihelping iidevelop iia iiregulatory iiintelligence iiprocedure iifor
iicontinuously iicollecting iiand iianalyzing iiregulatory iiinformation iipertaining iito
iichromosome iienumeration iiprobes ii(CEPs), iia iitype iiof iiin iivitro iidiagnostic ii(IVD)
iidevice. iiWhich iiof iithe iifollowing iiinputs iishould iibe iiconsidered iiwhen iicreating iithis
iiprocedure?


a) iiSources iiof iicontent ii(for iiexample ii- iiblogs iiand iiwhite iipapers)
b) iiIdentification iiof iiapplicable iigovernment iipublications iiand iiregulations
c) iiDatabases iicontaining iiinternational iistandards iiand iiguidelines
d) iiAll iioptions iilisted iiabove iishould iibe iiconsidered ii- iiAnswers ii-d) iiAll iioptions iilisted
iiabove iishould iibe iiconsidered


Explanation: ii
For iia iicomprehensive iiregulatory iiintelligence iiprocedure, iiit's iiimportant iito iiconsider iia
iivariety iiof iiinputs iiincluding iisources iiof iicontent, iigovernment iipublications, iiand
iidatabases iiof iistandards iiand iiguidelines iito iiensure iithorough iiand iiup-to-date
iiregulatory iianalysis.


According iito iiFDA, ii"remanufacturing" iiis iithe iiprocessing, iiconditioning, iirenovating,
iirepackaging, iirestoring, iior iiany iiother iiact iidone iito iia iifinished iidevice iithat iisignificantly
iichanges iiwhich iiof iithe iifollowing?


a) iiThe iiperformance/safety iispecification, iior iiintended iiuse iiof iithe iifinished iidevice
b) iiThe iiintended iiuse iior iifundamental iitechnology iiof iithe iidevice
c) iiThe iiperformance/safety iispecification iior iioperating iicharacteristics
d) iiThe iilabeling iiand/or iipackaging iiof iithe iifinished iidevice ii- iiAnswers ii-a) iiThe
iiperformance/safety iispecification, iior iiintended iiuse iiof iithe iifinished iidevice

, Explanation: ii
According iito iithe iiFDA, iiremanufacturing iiinvolves iisignificant iichanges iito iia iidevice
iithat iiaffect iiits iiperformance, iisafety iispecifications, iior iiintended iiuse.


In iithe iiUS, iiwhich iiof iithe iifollowing iiare iipermitted iito iibe iiincluded iiin iithe iiUDI
iiProduction iiIdentifier ii(PI) iion iia iidevice iilabel?


a) iiUniversal iiProduct iiCode ii(UPC) iiof iia iispecific iidevice
b) iiModel iinumber iiof iia iispecific iidevice
c) iiSerial iinumber iiof iia iispecific iidevice
d) iiB iiand iiC ii- iiAnswers ii-c) iiSerial iinumber iiof iia iispecific iidevice

Explanation: iiThe iiProduction iiIdentifier ii(PI) iiin iithe iiUDI iican iiinclude iithe iiserial
iinumber, iibut iinot iithe iiUniversal iiProduct iiCode ii(UPC) iior iimodel iinumber. iiThe iimodel
iinumber iiis iipart iiof iithe iiDevice iiIdentifier ii(DI), iinot iithe iiPI.


In iithe iicontext iiof iicybersecurity iiregulations, iia iilegacy iidevice iiis iione iithat:

a) iiHas iibeen iiin iiuse iiin iia iiclinical iienvironment iifor iilong iiperiods iiwithout iiupdates.
b) iiCannot iibe iireasonably iiprotected iiagainst iicurrent iicybersecurity iithreats
c) iiWas iidesigned iiand iideveloped iiprior iito iia iicompany's iiimplementation iiof
iicybersecurity iipolicies
d) iiHas iinot iibeen iireviewed iiby iian iiInformation iiSharing iiand iiAnalysis iiOrganization
ii(ISAO) ii- iiAnswers ii-b) iiCannot iibe iireasonably iiprotected iiagainst iicurrent
iicybersecurity iithreats


Explanation: ii
A iilegacy iidevice iiis iitypically iione iithat, iidue iito iiits iiage iior iidesign, iicannot iibe
iiadequately iiprotected iiagainst iimodern iicybersecurity iithreats.


A iicompany iiis iisubmitting iia iiPMA iifor iia iipermanent iiimplant. iiThe iicompany iihas
iiperformed iibiocompatibility iitesting iibased iion iiISO iirequirements iiand iibelieves iithe
iipackage iiis iicomplete. iiWhich iiof iithe iifollowing iitesting iidoes iithe iicompany iiabsolutely
iineed iito iidemonstrate iilong-term iisafety iiof iiits iidevice:


a) iiIntracutaneous iiirritation
b) iiGenotoxicity
c) iiAcutetoxicity
d) iiCarcinogenicity ii- iiAnswers ii-d) iiCarcinogenicity

Explanation: ii
Carcinogenicity iitesting iiis iicritical iifor iipermanent iiimplants iias iiit iiassesses iithe
iipotential iifor iithe iidevice iito iicause iicancer iiover iian iiextended iiperiod, iiwhich iiis
iiessential iifor iilong-term iisafety iievaluation.

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller millyphilip. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $13.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

80461 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$13.49
  • (0)
  Add to cart